拓展工具包以应对大流行病。
Expanding the toolbox to combat a pandemic.
机构信息
Memorial Sloan Kettering Cancer Center.
出版信息
Blood. 2020 Dec 17;136(25):2847-2848. doi: 10.1182/blood.2020009408.
Abstract
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for optimizing treatment of COVID-19. In this issue of , Keller and colleagues generated SARS-CoV-2–specific cytotoxic T lymphocytes (CTLs) from the blood of individuals recovered from infection. The rapid application of this good manufacturing practice (GMP)-compliant system raises the possibility that banked third-party SARS-CoV-2 CTLs could be used for treatment.
摘要
了解严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的免疫反应对于优化 COVID-19 的治疗至关重要。在本期 中，Keller 及其同事从感染后康复的个体的血液中生成了针对 SARS-CoV-2 的细胞毒性 T 淋巴细胞（CTL）。这种符合良好生产规范（GMP）的系统的快速应用提出了这样一种可能性，即可以使用第三方 SARS-CoV-2 CTL 进行治疗。
相似文献
1
Expanding the toolbox to combat a pandemic.拓展工具包以应对大流行病。
Blood. 2020 Dec 17;136(25):2847-2848. doi: 10.1182/blood.2020009408.
2
Ready and waiting to go.准备就绪，随时出发。
Elife. 2023 Jan 6;12:e85080. doi: 10.7554/eLife.85080.
3
Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology.阐明人类对 SARS-CoV-2 的 T 细胞和 B 细胞反应：深入了解保护性免疫和免疫病理学。
Cells. 2021 Dec 27;11(1):67. doi: 10.3390/cells11010067.
4
Humoral and T cell responses to SARS-CoV-2 reveal insights into immunity during the early pandemic period in Pakistan.体液免疫和 T 细胞应答对 SARS-CoV-2 的反应揭示了在巴基斯坦大流行早期期间的免疫情况。
BMC Infect Dis. 2023 Dec 1;23(1):846. doi: 10.1186/s12879-023-08829-1.
5
Concordance of B- and T-cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19.无论 COVID-19 症状是否明显，针对 SARS-CoV-2 感染的 B 细胞和 T 细胞反应的一致性。
J Med Virol. 2022 Nov;94(11):5217-5224. doi: 10.1002/jmv.28016. Epub 2022 Jul 30.
6
Are T cell repertoires useful as diagnostics for SARS- CoV- 2 infection?T细胞受体库能否作为新冠病毒感染的诊断方法？
Expert Rev Mol Diagn. 2021 Feb;21(2):137-139. doi: 10.1080/14737159.2021.1882852. Epub 2021 Feb 17.
7
[Are SARS-CoV-2 reactive T cells detectable and potentially protective in patients under anti-CD20 treatment with an impaired humoral response?].[在体液反应受损的接受抗CD20治疗的患者中，是否可检测到针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的反应性T细胞并具有潜在保护作用？]
Z Rheumatol. 2021 Nov;80(9):879-883. doi: 10.1007/s00393-021-01083-3. Epub 2021 Sep 16.
8
T cell-oriented strategies for controlling the COVID-19 pandemic.以 T 细胞为导向的策略控制 COVID-19 大流行。
Nat Rev Immunol. 2021 Nov;21(11):687-688. doi: 10.1038/s41577-021-00625-9.
9
Fresh versus frozen PMBC using the SARS CoV-2 T-SPOT.COVID test. Which works best?使用 SARS CoV-2 T-SPOT.COVID 试验检测新鲜与冷冻 PMBC。哪种效果最佳？
J Immunol Methods. 2022 Jul;506:113278. doi: 10.1016/j.jim.2022.113278. Epub 2022 May 6.
10
Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave.在首次大流行期间，COVID-19 病例的家庭接触者中轻度 COVID-19 患者的协调固有和 T 细胞免疫应答。
Front Immunol. 2022 Jul 27;13:920227. doi: 10.3389/fimmu.2022.920227. eCollection 2022.
本文引用的文献
1
SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein.SARS-CoV-2 特异性 T 细胞被快速扩增用于治疗，并针对膜蛋白的保守区域。
Blood. 2020 Dec 17;136(25):2905-2917. doi: 10.1182/blood.2020008488.
2
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation.造血干细胞移植受者 COVID-19 的良好结局。
J Clin Invest. 2020 Dec 1;130(12):6656-6667. doi: 10.1172/JCI141777.
3
T cell responses in patients with COVID-19.新冠病毒肺炎患者的T细胞反应
Nat Rev Immunol. 2020 Sep;20(9):529-536. doi: 10.1038/s41577-020-0402-6. Epub 2020 Jul 29.
4
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.COVID-19 疾病患者和未接触者体内针对 SARS-CoV-2 冠状病毒的 T 细胞反应的靶标。
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.
5
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia.B细胞在新冠病毒疾病中可能发挥的作用？来自无丙种球蛋白血症患者的启示。
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4. doi: 10.1016/j.jaci.2020.04.013. Epub 2020 Apr 22.
6
Adoptive cell therapies for posttransplant infections.移植后感染的过继细胞疗法。
Curr Opin Oncol. 2019 Nov;31(6):574-590. doi: 10.1097/CCO.0000000000000580.
7
Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction.HLA 限制性定义明确的病毒特异性 T 细胞提供的治疗优势。
Bone Marrow Transplant. 2019 Aug;54(Suppl 2):759-764. doi: 10.1038/s41409-019-0614-1.
8
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.通过转移供体的T细胞克隆来重建异基因骨髓受体针对巨细胞病毒的细胞免疫。
N Engl J Med. 1995 Oct 19;333(16):1038-44. doi: 10.1056/NEJM199510193331603.
Zotero 插件